FDA approves Guardant360 Liquid CDx test for Guardant Health

Guardant Health

Guardant Health

GH

0.00
  • FDA clearance granted for Guardant Health’s Guardant360 Liquid CDx, a next-generation liquid biopsy for advanced cancer.
  • The test expands the panel’s genomic footprint by 100x versus the prior Guardant360 CDx.
  • Seven existing FDA-approved companion diagnostic indications for Guardant360 CDx transfer to the new assay.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605200805BIZWIRE_USPR_____20260520_BW531436) on May 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.